Prevalence of Gastrointestinal and Cardiovascular Risk in Patients with Degenerative Lumbar Spinal Disease.

Autor:	Yang JH; Department of Orthopedic Surgery, Yonsei University College of Medicine, Seoul, Korea., Lee BH; Department of Orthopedic Surgery, Yonsei University College of Medicine, Seoul, Korea., Eum KS; Department of Orthopedic Surgery, Yonsei University College of Medicine, Seoul, Korea., Suk KS; Department of Orthopedic Surgery, Yonsei University College of Medicine, Seoul, Korea., Park JO; Department of Orthopedic Surgery, Yonsei University College of Medicine, Seoul, Korea., Kim HS; Department of Orthopedic Surgery, Yonsei University College of Medicine, Seoul, Korea., Lee HM; Department of Orthopedic Surgery, Yonsei University College of Medicine, Seoul, Korea., Moon SH; Department of Orthopedic Surgery, Yonsei University College of Medicine, Seoul, Korea.
Jazyk:	angličtina
Zdroj:	Clinics in orthopedic surgery [Clin Orthop Surg] 2020 Sep; Vol. 12 (3), pp. 343-352. Date of Electronic Publication: 2020 Aug 19.
DOI:	10.4055/cios20021
Abstrakt:	Background: Limited information is available about the proportion of patients with degenerative lumbar spinal disease (DLSD) who have gastrointestinal (GI) and cardiovascular (CV) risk factors. Many DLSD patients are prescribed nonsteroidal anti-inflammatory drugs (NSAIDs) that are known to carry risks to the GI and CV systems by increasing GI bleeding and thromboembolic events. This study aimed to measure the prevalence of GI and CV risk in patients with DLSD and to ascertain whether the prescription of NSAIDs is in line with current guidelines. Methods: This study included 153 patients with symptomatic DLSD who were planning to undergo lumbar spinal surgery. The GI profile was checked using the GI Standardized Calculator of Risk for Event system and CV risk was evaluated using the presence of metabolic syndrome. The conformity of the prescription of NSAIDs was investigated according to the recommendations in current guidelines. Results: More than half of the patients (59.5%) had high or very high GI risk, and 66% of the patients were diagnosed with metabolic syndrome, which corresponds with CV risk. The rate of simultaneous GI and CV risk was 40.5% (n = 62 / 153; gastrointestinal Standardized Calculator of Risk for Event, > high and metabolic syndrome, yes). The actual prescription of NSAIDs was not in accordance with current guidelines. Conclusions: Two out of 3 patients had GI or CV risk factors, and approximately 40% of patients had both. Detailed assessment of GI and CV risk in patients with DLSD by using effective evaluation tools is mandatory for optimal medical treatment. Competing Interests: CONFLICT OF INTEREST: No potential conflict of interest relevant to this article was reported. (Copyright © 2020 by The Korean Orthopaedic Association.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu